Experience with Subcutaneous Methotrexate for the Treatment of Moderate-to-Severe Psoriasis
نویسندگان
چکیده
Methods: The study enrolled 10 patients with moderate-to-severe psoriasis who presented at the outpatient dermatology clinic. Treatment comprised 15 mg of subcutaneous methotrexate, once weekly for 6 months. Data were obtained on demographic characteristics (Table 1), duration of psoriasis, Body Surface Area (BSA), and scores on the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI).
منابع مشابه
Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
Background Although oral methotrexate is an effective first-line traditional systemic therapy for psoriasis, the use of the subcutaneous form of methotrexate for the treatment of psoriasis has not been fully established. Objective This study is a literature review of the research related to the safety, efficacy, and patient acceptability of subcutaneous methotrexate for its application in the...
متن کاملDoes Short-Term Low-Dose Methotrexate Treatment Affect Homocysteine Blood Level in Patients with Psoriasis?
Background: An elevated homocysteine level is an independent risk factor for cardiovascular disorders. Psoriatic patients have an increased risk of cardiovascular diseases; In addition, hyperhomocysteinemia is a complication of methotrexate treatment. We undertook a study to evaluate the plasma levels of homocysteine, vitamin B12 and folate in patients with psoriasis before and after short-term...
متن کاملEtanercept combined with systemic drugs or phototherapy for treatment of psoriasis.
Biologic drugs have provided excellent results in the treatment of moderate to severe psoriasis. Nevertheless, in routine clinical practice, combinations of biologic drugs with phototherapy or systemic drugs can increase efficacy, diminish toxicity, and reduce the cost of treatment. Published experience with these combinations is scarce, although the results are often satisfactory. This review ...
متن کاملSerum vascular endothelial growth factor in Iranian patients with moderate-severe psoriasis before and after treatment: a PASI-75 response as a practical treatment goal
Background: Psoriasis is a chronic disease with multiple biochemical and vascular abnormalities. Several studies have evaluated circulating levels of vascular endothelial growth factor (VEGF) in psoriasis, but none of them evaluated it after reaching a PASI-75 response, as a practical treatment goal. The aim of this study was to evaluate serum levels of VEGF in moderate to severe psoriatic pati...
متن کاملPsoriasis: Current Therapeutical Strategies
Psoriasis is a chronic, genetically determined skin disease. A variety of biochemical and molecular biological alterations have been identified, but the pathogenesis of psoriasis is still not clear. For patients with mild to moderate psoriasis, topical therapies are generally used. However, approximately one-third of the patients have a moderate to severe psoriasis and need a systemic therapy. ...
متن کامل